Ozan Efesoy1, Murat Bozlu2, Selahittin Çayan2, Erdem Akbay2. 1. Clinic of Urology, Develi Hatice-Muammer Kocatürk State Hospital, Kayseri, Turkey. 2. Department of Urology, Faculty of Medicine, Mersin University, Mersin, Turkey.
Abstract
OBJECTIVE: Currently, transrectal ultrasound-guided (TRUS) systematic prostate biopsy is the standard procedure in the diagnosis of prostate cancer. Although TRUS-guided prostate biopsy is a safe method, it is an invasive procedure that is not free from complications. In this prospective study we evaluated the complications of a TRUS-guided 12-core prostate biopsy. MATERIAL AND METHODS: The study included 2049 patients undergoing transrectal ultrasound-guided 12-core prostate biopsy used in the diagnosis of prostate cancer. The indications for the prostate biopsy were abnormal digital rectal examination findings and/or an elevated serum total prostate specific antigen (PSA) level (greater than 4 ng/mL). The participants received prophylactic oral ciprofloxacin (500 mg) the night before and the morning of the biopsy, followed by 500 mg orally twice daily for 2 days. To prevent development of voiding disorders, the patients also received oral alpha blockers for 30 days starting the day before the procedure. A Fleet enema was self-administered the night before the procedure for rectal cleansing. The complications were assessed both 10 days and 1 month after the biopsy. RESULTS: The mean age, serum total PSA level and prostate volume of the patients were 65.4±9.6 years, 18.6±22.4 ng/mL and 51.3±22.4 cc, respectively. From these 2.042 biopsies, 596 cases (29.1%) were histopathologically diagnosed as prostate adenocarcinoma. Minor complications, such as hematuria (66.3%), hematospermia (38.8%), rectal bleeding (28.4%), mild to moderate degrees of vasovagal episodes (7.7%), and genitourinary tract infection (6.1%) were noted frequently. Major complications were rare and included urosepsis (0.5%), rectal bleeding requiring intervention (0.3%), acute urinary retention (0.3%), hematuria necessitating transfusion (0.05%), Fournier's gangrene (0.05%), and myocardial infarction (0.05%). CONCLUSION: TRUS-guided prostate biopsy is safe for diagnosing prostate cancer with few major but frequent minor complications. However, patients should be informed and followed-up after biopsy regarding possible complications.
OBJECTIVE: Currently, transrectal ultrasound-guided (TRUS) systematic prostate biopsy is the standard procedure in the diagnosis of prostate cancer. Although TRUS-guided prostate biopsy is a safe method, it is an invasive procedure that is not free from complications. In this prospective study we evaluated the complications of a TRUS-guided 12-core prostate biopsy. MATERIAL AND METHODS: The study included 2049 patients undergoing transrectal ultrasound-guided 12-core prostate biopsy used in the diagnosis of prostate cancer. The indications for the prostate biopsy were abnormal digital rectal examination findings and/or an elevated serum total prostate specific antigen (PSA) level (greater than 4 ng/mL). The participants received prophylactic oral ciprofloxacin (500 mg) the night before and the morning of the biopsy, followed by 500 mg orally twice daily for 2 days. To prevent development of voiding disorders, the patients also received oral alpha blockers for 30 days starting the day before the procedure. A Fleet enema was self-administered the night before the procedure for rectal cleansing. The complications were assessed both 10 days and 1 month after the biopsy. RESULTS: The mean age, serum total PSA level and prostate volume of the patients were 65.4±9.6 years, 18.6±22.4 ng/mL and 51.3±22.4 cc, respectively. From these 2.042 biopsies, 596 cases (29.1%) were histopathologically diagnosed as prostate adenocarcinoma. Minor complications, such as hematuria (66.3%), hematospermia (38.8%), rectal bleeding (28.4%), mild to moderate degrees of vasovagal episodes (7.7%), and genitourinary tract infection (6.1%) were noted frequently. Major complications were rare and included urosepsis (0.5%), rectal bleeding requiring intervention (0.3%), acute urinary retention (0.3%), hematuria necessitating transfusion (0.05%), Fournier's gangrene (0.05%), and myocardial infarction (0.05%). CONCLUSION: TRUS-guided prostate biopsy is safe for diagnosing prostate cancer with few major but frequent minor complications. However, patients should be informed and followed-up after biopsy regarding possible complications.
Authors: B Djavan; M Waldert; A Zlotta; P Dobronski; C Seitz; M Remzi; A Borkowski; C Schulman; M Marberger Journal: J Urol Date: 2001-09 Impact factor: 7.450
Authors: Andreas P Berger; Christian Gozzi; Hannes Steiner; Ferdinand Frauscher; John Varkarakis; Hermann Rogatsch; Georg Bartsch; Wolfgang Horninger Journal: J Urol Date: 2004-04 Impact factor: 7.450
Authors: Roger Paul; Stefan Schöler; Heiner van Randenborgh; Hubert Kübler; Michael Alschibaja; Raymonde Busch; Rudolf Hartung Journal: Eur Urol Date: 2004-04 Impact factor: 20.096
Authors: Mustafa Bilal Hamarat; Fatih Tarhan; Rahim Horuz; Gülfem Akengin Öcal; Mehmet Kutlu Demirkol; Alper Kafkaslı; Özgür Yazıcı Journal: Turk J Urol Date: 2017-05-03
Authors: Adnan Malik; Rizwan Ishtiaq; Muhammad Hassan Naeem Goraya; Faisal Inayat; Vinaya V Gaduputi Journal: J Investig Med High Impact Case Rep Date: 2021 Jan-Dec
Authors: Neel H Patel; Jonathan Bloom; Joel Hillelsohn; Sean Fullerton; Denton Allman; Gerald Matthews; Majid Eshghi; John L Phillips Journal: Health Equity Date: 2018-05-01